Accumulus Synergy Responds Food and Drug Administration’s Information Technology Strategy
Biopharmaceutical companies push the boundaries of science to develop medicines, employ the most sophisticated techniques to visualize and analyze data, and then painstakingly transfer the results onto paper or PDFs to communicate data to regulators.
Continue ReadingAccumulus Synergy Responds to FDA’s Draft Pharmaceutical Quality/Chemistry Manufacturing and Controls (PQ/CMC) Data Exchange
Biopharmaceutical companies push the boundaries of science to develop medicines, employ the most sophisticated techniques to visualize and analyze data, and then painstakingly transfer the results onto paper or PDFs to communicate data to regulators.
Continue Reading